



Brazilian Journal of Cardiovascular Surgery

ISSN: 0102-7638

ISSN: 1678-9741

Sociedade Brasileira de Cirurgia Cardiovascular

Stefen, Samuel Padovani; Tenório, Davi Freitas; Cirillo, Guilherme Carvalho Gnipper; Gaspar, Shirlyne Fabianni; Oliveira, Karen Amanda Soares de; Gaiotto, Fábio Antonio; Jatene, Fabio B.

Severe and Moderate Primary Graft Dysfunction in Adult Heart Recipients

Brazilian Journal of Cardiovascular Surgery, vol. 38, no. 2, 2023, March-April, pp. 214-218

Sociedade Brasileira de Cirurgia Cardiovascular

DOI: <https://doi.org/10.21470/1678-9741-2022-0107>

Available in: <https://www.redalyc.org/articulo.oa?id=398974952002>

- ▶ [How to cite](#)
- ▶ [Complete issue](#)
- ▶ [More information about this article](#)
- ▶ [Journal's webpage in redalyc.org](#)

The logo for Redalyc.org, featuring the text 'redalyc.org' in a stylized font with a red dot above the 'y'.

Scientific Information System Redalyc

Network of Scientific Journals from Latin America and the Caribbean, Spain and Portugal

Project academic non-profit, developed under the open access initiative

# Severe and Moderate Primary Graft Dysfunction in Adult Heart Recipients

Samuel Padovani Steffen<sup>1</sup>, MD; Davi Freitas Tenório<sup>1</sup>, MD; Guilherme Carvalhal Gnipper Cirillo<sup>1</sup>, MD; Shirlyne Fabianni Gaspar<sup>1</sup>, MD; Karen Amanda Soares de Oliveira<sup>2</sup>, MD; Fábio Antonio Gaiotto<sup>1</sup>, MD, PhD; Fabio B. Jatene<sup>1</sup>, MD, PhD

<sup>1</sup>Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (InCor-HCFMUSP), São Paulo, São Paulo, Brazil.

<sup>2</sup>Cardiac Surgery Department, Faculdade de Medicina, Universidade Federal de Goiás (FMUFG), Goiânia, Goiás, Brazil.

This study was carried out at Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (InCor-HCFMUSP), São Paulo, São Paulo, Brazil.

## ABSTRACT

**Introduction:** The aims of this study were to determine the incidence of severe and moderate primary graft dysfunction (PGD) in our center, to identify, retrospectively, donors' and recipients' risk factors for PGD development, and to evaluate the impact of PGD within 30 days after heart transplantation.

**Methods:** Donors' and recipients' medical records of 64 consecutive adult cardiac transplantations performed between January 2016 and June 2017 were reviewed. The International Society for Heart and Lung Transplantation (ISHLT) criteria were used to diagnose moderate and severe PGD. Associations of risk factors for combined moderate/severe PGD were assessed with appropriate statistical analyses.

**Results:** Sixty-four patients underwent heart transplantation in this period. Twelve recipients (18.7%) developed severe or moderate PGD. Development of PGD was associated with previous donor cardiopulmonary resuscitation and a history of prior heart surgery in the recipient ( $P=0.01$  and  $P=0.02$ , respectively). The 30-day in hospital mortality was similar in both PGD and non-PGD patients.

**Conclusion:** The use of the ISHLT criteria for PGD is important to identify potential risk factor. The development of PGD did not affect short-term survival in our study. More studies should be done to better understand the pathophysiology of PGD.

**Keywords:** Cardiopulmonary Resuscitation. Primary Graft Dysfunction. Heart Transplantation. Tissue Donors. Risk Factors.

## Abbreviations, Acronyms & Symbols

BiVAD	= Biventricular assist device	MAP	= Mean arterial pressure
CI	= Cardiac index	PCWP	= Pulmonary capillary wedge pressure
CPR	= Cardiopulmonary resuscitation	PGD	= Primary graft dysfunction
ECMO	= Extracorporeal membrane oxygenation	PGD-LV	= Left ventricular primary graft dysfunction
IABP	= Intra-aortic balloon pump	PGD-RV	= Right ventricular primary graft dysfunction
ICU	= Intensive care unit	RAP	= Right atrial pressure
ISHLT	= International Society for Heart and Lung Transplantation	RVAD	= Right ventricular assist device
LVAD	= Left ventricular assist device	TPG	= Transpulmonary pressure gradient
LVEF	= Left ventricular ejection fraction	VAD	= Ventricular assist device

Correspondence Address:

Samuel Padovani Steffen

<https://orcid.org/0000-0001-6553-2305>

Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 44, Cerqueira César, São Paulo, SP, Brazil

Zip Code: 05403-000

E-mail: samuel.steffen@incor.usp.br

Article received on March 7<sup>th</sup>, 2022.

Article accepted on July 14<sup>th</sup>, 2022.

**INTRODUCTION**

The outcomes after heart transplantation have improved over the last years, with the mean survival being approximately ten years nowadays<sup>[1,2]</sup>. Despite this improvement, several factors still contribute to the morbidity and mortality of patients undergoing heart transplantation. In this context, primary graft dysfunction (PGD) is the main cause of early mortality after this procedure<sup>[3,4]</sup>. The most recent report from the International Society for Heart and Lung Transplantation (ISHLT) Registry reported that 42.6% of deaths within 30 days after heart transplantation were due to PGD<sup>[5]</sup>. Due to the lack of standardized criteria for its diagnosis, the incidence of PGD reported in the literature has varied widely between two and 24%<sup>[6,7]</sup>. To discuss this issue, the ISHLT recently published a consensus with standardized criteria for PGD<sup>[8]</sup>. The ISHLT consensus emphasized that the diagnosis of PGD must be made within 24 hours after completion of the transplantation surgery, and that other discernible causes such as hyper-acute rejection, pulmonary hypertension, or known surgical complications must be ruled out in order to diagnose PGD. The objectives of this study are to determine the incidence of severe and moderate PGD in our center using the ISHLT criteria, to identify, retrospectively, donors' and recipients' risk factors for PGD development, and to evaluate the impact of PGD within 30 days after heart transplantation.

**METHODS**

This study was approved by our institutional committee (CAAE: 86764218.1.0000.0068). The medical records of 64 patients undergoing heart transplantation procedures from January 2016 to June 2017 were reviewed. Information about the respective

donors was also reviewed. Recipients' characteristics examined were demographics, etiology of heart failure, and mechanical assistance prior to transplant. Donors' characteristics included demographics, cause of death, and hemodynamics/use of inotropic support. Procedural characteristics included distance from the donors' centers to the recipients' centers, extracorporeal mean time, and cold ischemia time. The ISHLT recently published standardized criteria were used to diagnose PGD (Table 1). Donor heart procurement was performed according to a standard procedure using 3000 ml of Custodiol® solution for preservation of the donor's heart. All transplant procedures were performed with a bicaval technique, and the same immunosuppression protocol was prescribed to all patients.

**RESULTS**

Baseline characteristics of donors and recipients are listed in Tables 2 and 3, respectively. The mean donor age was 33.4 years, and 90.6% of them were male. The etiology of brain death in the majority of cases was head trauma, followed by intracranial hemorrhage; and 78.1% of the donors were in use of inotropic support. There were 24 cases with a > 200 km distance from the donor's to the recipient's center. Cold ischemia mean time was 156 minutes (Table 4).

Most of the recipients were male (65.5%), with mean age of 49.5 years. The most common etiology of heart failure was dilated cardiomyopathy (37.6%), followed by Chagas disease (31.2%), and ischemic cardiomyopathy (25%). The majority of patients (98.4%) were hospitalized in priority, receiving inotropic support only (45.3%) or some type of left ventricular assist device (LVAD), with intra-aortic balloon pump being the most prevalent (46.8%). Two patients (3.3%) required extracorporeal membrane oxygenation,

**Table 1.** The International Society for Heart and Lung Transplantation definition scale for primary graft dysfunction (PGD)<sup>[9]</sup>.

Left ventricular PGD (PGD-LV)	Mild PGD-LV (one of the following criteria must be met)	LVEF < 40% by echocardiography or hemodynamics with RAP > 15 mmHg, PCWP > 20 mmHg, CI < 2.0 L/min/m <sup>2</sup> (lasting > 1 h) requiring low-dose inotropes.
	Moderate PGD-LV (must meet one criterion from I and another criterion from II)	I. LVEF < 40% or hemodynamic compromise with RAP > 15 mmHg, PCWP > 20 mmHg, CI < 2.0 L/min/m <sup>2</sup> , hypotension with MAP < 70 mmHg (lasting > 1 h). II. High-dose inotropes — inotrope score > 10* or newly placed IABP (regardless of inotropes).
	Severe PGD-LV	Dependence on left or biventricular mechanical support including ECMO, LVAD, BiVAD, or percutaneous LVAD. Excludes requirement for IABP.
Right ventricular PGD (PGD-RV)	Diagnosis requires either both i and ii, or iii alone	i. Hemodynamics with RAP > 15 mmHg, PCWP < 15 mmHg, CI < 2.0 L/min/m <sup>2</sup> .
		ii. TPG < 15 mmHg and/or pulmonary artery systolic pressure < 50 mmHg.
		iii. Need for RVAD.

BiVAD=biventricular assist device; CI=cardiac index; ECMO=extracorporeal membrane oxygenation; IABP=intra-aortic balloon pump; LVAD=left ventricular assist device; LVEF=left ventricular ejection fraction; MAP=mean arterial pressure; PCWP=pulmonary capillary wedge pressure; RAP=right atrial pressure; RVAD=right ventricular assist device; TPG=transpulmonary pressure gradient  
\*Inotrope score = dopamine (1) + dobutamine (1) + amrinone (1) + milrinone (15) + epinephrine (100) + norepinephrine (100) with each drug dosed in mg/kg/min

**Table 2.** Donors' characteristics.

	Overall (64)
Age, years (mean)	33.4
Cause of brain death	
Head trauma	44 (68.7%)
Intracranial hemorrhage	14 (21.8%)
Other	6 (9.5%)
Sex	
Male	58 (90.6%)
Female	6 (9.4%)
Use of inotropic support	50 (78.1%)

**Table 3.** Recipients' characteristics.

	Overall (64)
Age, years (mean)	49.5
Male sex (%)	62.5
Etiology	
Dilated cardiomyopathy	24 (37.6%)
Ischemic cardiomyopathy	16 (25%)
Chagas disease	20 (31.2%)
Others	4 (6.2%)
LVAD support	
IABP	30 (46.8%)
ECMO	2 (3.3%)
Others	3 (4.6%)
Use of inotropic support	29 (45.3%)

CMO=extracorporeal membrane oxygenation; IABP=intra-aortic balloon pump; LVAD=left ventricular assist device

**Table 4.** Procedural characteristics.

Distance from the donor's center (> 200 km)	24
Extracorporeal mean time (min)	73
Cold ischemia time (min)	156

two patients (3.3%) were in use of LVAD – InCor® support, and only one (1.5%) patient required left Centrimag® support prior to heart transplantation.

A total of 12 (18.7%) patients were diagnosed with moderate or severe PGD using the ISHLT criteria. Of the 12 recipients with PGD, three had right ventricular PGD, six had left ventricular PGD, and three had biventricular PGD. The patients were divided into PGD group and non-PGD group for statistical analysis. The variables compared were recipient-related, donor-related, and procedure-related, and are listed in Table 5.

With regard to donors' characteristics, most variables show no significant differences between the PGD group and the non-PGD group. The only possible predictor of PGD was donor's previous cardiopulmonary resuscitation (CPR) ( $P=0.01$ ). Among recipients' characteristics, a redo operation was identified as a possible

predictor of PGD ( $P=0.02$ ). These findings are shown in Table 5. With regard to postoperative early survival, there were four (6.25%) deaths in the first 30 postoperative days. Among the PGD patients, there was only one (8.3%) death in the early postoperative period, and the other 11 patients (91.6% of all PGD patients) survived the first 30 postoperative days.

## DISCUSSION

Heart transplantation is still the best therapy for patients with advanced heart failure who do not respond to conventional treatments<sup>[9]</sup>. Although survival after cardiac transplantation has been improving for the last two decades, the incidence and mortality from PGD is unclear from the literature but it is the most common cause of early mortality<sup>[8,10]</sup>.

**Table 5.** Comparison between primary graft dysfunction (PGD) and non-PGD groups.

Variable	Non-PGD	Moderate/severe PGD	P-value
<b>Recipients' variables</b>	<b>Overall (52)</b>	<b>Overall (12)</b>	
Age (mean), years	49.85	45.5	0.44
Gender, female	28 (53.8%)	4 (33.3%)	0.39
Ischemic cardiomyopathy	12 (23.0%)	3 (25%)	0.30
Non-ischemic cardiomyopathy	40 (67%)	9 (75%)	0.35
VAD prior to transplant	28 (54.7%)	6 (50%)	0.75
Prior sternotomy	3 (5.7%)	3 (25%)	0.02
ICU prior to transplant	31 (59.6%)	6 (50%)	0.34
<b>Donors' variables</b>			
Age (mean)	32	30	0.35
Head trauma	34 (65.3%)	7 (58.3%)	0.83
Other cause of death	18 (34.7%)	5 (41.7%)	0.82
Previous CPR	0	2 (16.6%)	0.01
Inotropic support (not > 0.1 ug/kg/min)	46.15 (24%)	7 (58.33%)	0.2
<b>Procedure-related variables</b>			
Distance from the donor's center to the transplant center (> 200 km)	19 (36.5%)	5 (41.5%)	0.4
Ischemic mean time (min)	148	155	0.76

The Chi-square test was used for categorical variables. Comparisons between the groups were made using the paired *t*-test CPR=cardiopulmonary resuscitation; ICU=intensive care unit; VAD=ventricular assist device

Some previous studies have shown that the incidence of PGD ranges from two to > 20%<sup>[11-14]</sup>. This wide range in the reported incidence of PGD is largely due to inconsistent definitions of PGD across studies. Recently, a report from a consensus conference on PGD proposing standardized criteria for PGD was published<sup>[8]</sup>. Based on these standard criteria, the incidence rate of moderate and severe PGD at our institution was 18.7%, which is consistent with other recent studies<sup>[15]</sup>. Since we did not report the mild cases, the total incidence of PGD in our center would probably be > 25% of all adult's transplants. This likely reflects the liberal criteria for PGD proposed by the ISHLT, that recognized that using this definition, a significant number of patients would be diagnosed with PGD<sup>[16]</sup>. In our study, we only reported the moderate and severe cases since it is not clear in the literature that mild PGD would somehow impact in morbidity and mortality after heart transplant<sup>[16]</sup>.

The pathogenesis of PGD has not been clearly delineated, though its origin is believed to be multifactorial. In one recent study, a longer period of hospitalization and recipients hospitalized at time of transplantation were found to be predictive of PGD<sup>[17]</sup>. Our study identified that all PGD recipients were hospitalized at the time of transplantation.

Numerous clinical markers indicating a more severe pre-transplant condition of the recipient, including requirement for inotropic or mechanical support, have been identified as risk factors for PGD suggesting that placing a donor's heart in a "hostile" recipient environment increases the risk for this complication<sup>[6-15-17]</sup>.

The donors' and recipients' factors predictive of PGD also vary widely. In the present study, donor's previous CPR e redo surgery

were identified as possible predictive factors for the development of PGD. In others studies, high-dose inotrope use in the donor's heart was identified as predictive factor<sup>[15]</sup>, but we did not found statistical difference regarding this issue.

Although PGD was previously thought to impact survival primarily within a 30-day postoperative period, recent evidence suggests that PGD may affect survival for several months beyond the initial post-transplantation period<sup>[17]</sup>. In our study, the in-hospital/30-day mortality for patients with PGD was similar to that for those patients without PGD, that is 8.3% and 5.7%, respectively. A longer follow-up would better evaluate these findings.

### Limitations

This study has several limitations, since it is a retrospective single-center study, with a small number of patients, and with a short 30-day follow-up. More studies should be done applying the ISHLT criteria, mainly in large and contemporary series. This will help to identify potential risk factors of PGD prior to heart transplantation. Also, future prospective studies should be delineated to better understand the pathophysiology of PGD, including possible predictive biomarkers.

### CONCLUSION

The use of the ISHLT criteria for PGD in a large center is important to identify patients at risk for the development of PGD. In our series, PGD did not affect short-term survival. Further studies are necessary to better understand the pathophysiology of PGD.

**No financial support.**  
**No conflict of interest.**

#### Authors' Roles & Responsibilities

SPS	Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
DFT	Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published
GCGC	Drafting the work or revising it critically for important intellectual content; final approval of the version to be published
SFG	Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
KASO	Drafting the work or revising it critically for important intellectual content; final approval of the version to be published
FAG	Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published
FBJ	Final approval of the version to be published

#### REFERENCES

1. Taylor DO, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, et al. Registry of the international society for heart and lung transplantation: twenty-fifth official adult heart transplant report--2008. *J Heart Lung Transplant.* 2008;27(9):943-56. doi:10.1016/j.healun.2008.06.017.
2. Khush KK, Valantine HA. New developments in immunosuppressive therapy for heart transplantation. *Expert Opin Emerg Drugs.* 2009;14(1):1-21. doi:10.1517/14728210902791605.
3. Sulemanjee NZ, Merla R, Lick SD, Aunon SM, Taylor M, Manson M, et al. The first year post-heart transplantation: use of immunosuppressive drugs and early complications. *J Cardiovasc Pharmacol Ther.* 2008;13(1):13-31. doi:10.1177/1074248407309916.
4. Hunt SA, Haddad F. The changing face of heart transplantation. *J Am Coll Cardiol.* 2008;52(8):587-98. doi:10.1016/j.jacc.2008.05.020.
5. Kobashigawa J, Zuckermann A, Macdonald P, LePrince P, Esmailian F, Luu M, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *J Heart Lung Transplant.* 2014;33(4):327-40. doi:10.1016/j.healun.2014.02.027.
6. Russo MJ, Iribarne A, Hong KN, Ramlawi B, Chen JM, Takayama H, et al. Factors associated with primary graft failure after heart transplantation. *Transplantation.* 2010;90(4):444-50. doi:10.1097/TP.0b013e3181e6f1eb.
7. Ibrahim M, Hendry P, Masters R, Rubens F, Lam BK, Ruel M, et al. Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. *Can J Cardiol.* 2007;23(5):363-7. doi:10.1016/s0828-282x(07)70769-9.
8. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report--2011. *J Heart Lung Transplant.* 2011;30(10):1078-94. doi:10.1016/j.healun.2011.08.003.
9. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report--2013; focus theme: age. *J Heart Lung Transplant.* 2013;32(10):951-64. doi:10.1016/j.healun.2013.08.006.
10. Fujita T, Toda K, Yanase M, Seguchi O, Murata Y, Ishibashi-Ueda H, et al. Risk factors for post-transplant low output syndrome. *Eur J Cardiothorac Surg.* 2012;42(3):551-6. doi:10.1093/ejcts/ezs032.
11. Iyer A, Kumarasinghe G, Hicks M, Watson A, Gao L, Doyle A, et al. Primary graft failure after heart transplantation. *J Transplant.* 2011;2011:175768. doi:10.1155/2011/175768.
12. Amarelli C, De Santo LS, Marra C, Maiello C, Bancone C, Della Corte A, et al. Early graft failure after heart transplant: risk factors and implications for improved donor-recipient matching. *Interact Cardiovasc Thorac Surg.* 2012;15(1):57-62. doi:10.1093/icvts/ivs113.
13. Seguchi O, Fujita T, Murata Y, Sunami H, Sato T, Watanabe T, et al. Incidence, etiology, and outcome of primary graft dysfunction in adult heart transplant recipients: a single-center experience in Japan. *Heart Vessels.* 2016;31(4):555-62. doi:10.1007/s00380-015-0649-1.
14. Squiers JJ, Saracino G, Chamogeorgakis T, MacHannaford JC, Rafael AE, Gonzalez-Stawinski GV, et al. Application of the international society for heart and lung transplantation (ISHLT) criteria for primary graft dysfunction after cardiac transplantation: outcomes from a high-volume centre. *Eur J Cardiothorac Surg.* 2017;51(2):263-70. doi:10.1093/ejcts/ezw271.
15. Cosío Carmena MD, Gómez Bueno M, Almenar L, Delgado JF, Arizón JM, González Vilchez F, et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. *J Heart Lung Transplant.* 2013;32(12):1187-95. doi:10.1016/j.healun.2013.08.004.
16. D'Alessandro C, Golmard JL, Barreda E, Laali M, Makris R, Luyt CE, et al. Predictive risk factors for primary graft failure requiring temporary extra-corporeal membrane oxygenation support after cardiac transplantation in adults. *Eur J Cardiothorac Surg.* 2011;40(4):962-9. doi:10.1016/j.ejcts.2011.01.064.
17. Hong KN, Iribarne A, Worku B, Takayama H, Gelijns AC, Naka Y, et al. Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors. *Ann Thorac Surg.* 2011;92(2):520-7; discussion 527. doi:10.1016/j.athoracsur.2011.02.086.

